KYORIN Pharmaceutical

4569.T

Tokyo, Japan· Est. 1950

kyorin-pharm.co.jp

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

4569.T · Stock Price

JPY 1,550+62 (+4.17%)

Market Cap: $568.9M

Historical price data

Market Cap: $568.9MPipeline: 5 drugs (1 Phase 3)Patents: 20Founded: 1950HQ: Tokyo, Japan

Sector Ranking#56 in Small Molecule Drugs

Overview

KYORIN Pharmaceutical is a publicly listed Japanese pharmaceutical leader with a mission to contribute to people's health by addressing unmet medical needs. Founded in 1923 and publicly listed in 1999, the company has achieved significant scale with a market valuation of ~$94.8B, built on a foundation of established products in respiratory and urology. Its current strategy, outlined in the 'Vision 110' long-term plan, focuses on transforming its business structure to become a core innovator in new pharmaceuticals while expanding its healthcare portfolio.

RespiratoryUrologyOtolaryngologyInfectious DiseasePain

Technology Platform

A therapeutic area-focused, integrated R&D platform built on decades of expertise in quinolone antimicrobials, receptor pharmacology, and inflammation, supplemented by strategic in-licensing and out-licensing partnerships.

Pipeline

5 drugs in pipeline1 in Phase 3

Drug	Indication	Stage
Imidafenacin + Fesoterodine	Overactive Bladder	Approved
Efzofitimod 3 mg/kg + Efzofitimod 5 mg/kg + Placebo	Pulmonary Sarcoidosis	Phase 3
KRP-104 QD Drug: Placebo Drug: Metformin + Placebo Drug: Met...	Type 2 Diabetes	Phase 2
KRP-104 + Placebo	Type 2 Diabetes	Phase 2
KRP-A218 + Placebo + itraconazole	Healthy	Phase 1

Opportunities

Significant growth potential from the flagship chronic cough drug Refuna, expansion into adjacent markets like neuropathic pain through in-licensing, and a stable revenue base from OTC brands and an aging Japanese population.

Risk Factors

Heavy reliance on the Japanese market exposes the company to domestic pricing pressures and demographic shifts.

Pipeline success is concentrated on a few key assets like Refuna, and the company faces intense competition from larger global and domestic pharmaceutical firms.

Competitive Landscape

KYORIN competes with large domestic pharma (Takeda, Astellas) and multinational corporations in its core therapeutic areas, relying on deep niche expertise and domestic relationships. In OTC and generics, it faces broad competition from global consumer health and generic manufacturers.